1. Home
  2. WVE vs ARQT Comparison

WVE vs ARQT Comparison

Compare WVE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$6.19

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$21.25

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
ARQT
Founded
2012
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
WVE
ARQT
Price
$6.19
$21.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
6
Target Price
$29.81
$34.00
AVG Volume (30 Days)
3.9M
2.1M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
N/A
N/A
Revenue
$3,704,000.00
$376,072,000.00
Revenue This Year
N/A
$34.85
Revenue Next Year
$85.67
$29.39
P/E Ratio
N/A
N/A
Revenue Growth
149.43
91.34
52 Week Low
$5.02
$12.72
52 Week High
$21.73
$31.77

Technical Indicators

Market Signals
Indicator
WVE
ARQT
Relative Strength Index (RSI) 35.45 46.11
Support Level $6.02 $21.12
Resistance Level $7.65 $21.84
Average True Range (ATR) 0.35 0.98
MACD 0.05 0.13
Stochastic Oscillator 15.04 61.97

Price Performance

Historical Comparison
WVE
ARQT

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: